CTAS vs. BMY
CTAS (Cintas Corporation) and BMY (Bristol-Myers Squibb Company) are both stocks. CTAS operates in Specialty Business Services (Industrials), while BMY operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, CTAS returned 23.61%/yr vs 1.00%/yr for BMY. At a 0.26 correlation, their price movements are largely independent.
Performance
CTAS vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CTAS achieves a -5.80% return, which is significantly lower than BMY's 8.27% return. Over the past 10 years, CTAS has outperformed BMY with an annualized return of 23.61%, while BMY has yielded a comparatively lower 1.00% annualized return.
CTAS
- 1D
- -3.08%
- 1M
- 6.51%
- YTD
- -5.80%
- 6M
- -5.53%
- 1Y
- -19.83%
- 3Y*
- 14.43%
- 5Y*
- 15.92%
- 10Y*
- 23.61%
BMY
- 1D
- 0.40%
- 1M
- 0.63%
- YTD
- 8.27%
- 6M
- 11.43%
- 1Y
- 20.57%
- 3Y*
- 0.45%
- 5Y*
- 0.73%
- 10Y*
- 1.00%
CTAS vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CTAS Cintas Corporation | -5.80% | 3.78% | 22.24% | 34.82% | 2.97% | 26.51% | 32.74% | 61.73% | 9.04% | 36.32% |
BMY Bristol-Myers Squibb Company | 8.27% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Correlation
The correlation between CTAS and BMY is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Mar 26, 1990 | 0.26 |
Fundamentals
CTAS:
$71.72B
BMY:
$116.75B
CTAS:
$4.75
BMY:
$3.57
CTAS:
37.08
BMY:
16.02
CTAS:
2.60
BMY:
0.91
CTAS:
6.51
BMY:
2.40
CTAS:
14.98
BMY:
5.82
CTAS:
$11.03B
BMY:
$48.48B
CTAS:
$1.33B
BMY:
$33.33B
CTAS:
$2.66B
BMY:
$13.34B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CTAS vs. BMY — Risk / Return Rank
CTAS
BMY
CTAS vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cintas Corporation (CTAS) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CTAS | BMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.69 | ||
| Sortino ratioReturn per unit of downside risk | -2.52 | ||
| Omega ratioGain probability vs. loss probability | 0.84 | 1.14 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | -0.75 | 1.53 | -2.28 |
| Martin ratioReturn relative to average drawdown | -1.31 | 3.32 | -4.63 |
Loading charts...
Drawdowns
CTAS vs. BMY - Drawdown Comparison
The maximum CTAS drawdown since its inception was -65.32%, smaller than the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for CTAS and BMY.
Loading charts...
Drawdown Indicators
| CTAS | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -65.32% | -72.03% | +6.71% |
Max Drawdown (1Y)Largest decline over 1 year | -27.23% | -12.05% | -15.18% |
Max Drawdown (3Y)Largest decline over 3 years | -27.68% | -36.85% | +9.17% |
Max Drawdown (5Y)Largest decline over 5 years | -27.68% | -47.67% | +19.99% |
Max Drawdown (10Y)Largest decline over 10 years | -48.38% | -47.67% | -0.71% |
Current DrawdownCurrent decline from peak | -21.83% | -17.79% | -4.04% |
Average DrawdownAverage peak-to-trough decline | -15.04% | -22.38% | +7.34% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.61% | 6.34% | +9.27% |
Volatility
CTAS vs. BMY - Volatility Comparison
Cintas Corporation (CTAS) and Bristol-Myers Squibb Company (BMY) have volatilities of 8.54% and 8.22%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CTAS | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.54% | 8.22% | +0.32% |
Volatility (6M)Calculated over the trailing 6-month period | 15.74% | 18.18% | -2.44% |
Volatility (1Y)Calculated over the trailing 1-year period | 20.40% | 27.08% | -6.68% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.60% | 24.02% | -1.42% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 26.70% | 25.29% | +1.41% |
Dividends
CTAS vs. BMY - Dividend Comparison
CTAS's dividend yield for the trailing twelve months is around 1.02%, less than BMY's 4.38% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.38% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
CTAS Cintas Corporation | 1.02% | 0.89% | 0.80% | 0.83% | 0.93% | 0.77% | 0.99% | 0.95% | 1.22% | 1.04% | 1.15% | 1.15% |
Financials
CTAS vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Cintas Corporation and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CTAS vs. BMY - Profitability Comparison
CTAS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cintas Corporation reported a gross profit of -2.78B and revenue of 2.84B. Therefore, the gross margin over that period was -97.8%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.
CTAS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cintas Corporation reported an operating income of 659.90M and revenue of 2.84B, resulting in an operating margin of 23.2%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.
CTAS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cintas Corporation reported a net income of 502.50M and revenue of 2.84B, resulting in a net margin of 17.7%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.
Frequently Asked Questions
CTAS and BMY have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CTAS has higher volatility (8.54%) compared to BMY (8.22%). In terms of maximum drawdown, CTAS dropped -65.32% vs BMY's -72.03%.
BMY currently has the higher Sharpe Ratio (0.68 vs -1.00), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CTAS and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer